Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: Prospective analysis of 435 liver biopsy pairs

Monica A. Konerman, Shruti H. Mehta, Catherine G. Sutcliffe, Trang Vu, Yvonne Higgins, Michael S. Torbenson, Richard D. Moore, David L. Thomas, Mark S. Sulkowski – 20 September 2013 – Human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfection is associated with progressive liver disease. However, the rate of progression is variable and the ability to differentiate patients with stable versus progressive HCV disease is limited. The objective of this study was to assess the incidence of and risk factors for fibrosis progression in a prospective cohort of coinfected patients.

Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: Prospective analysis of 435 liver biopsy pairs

Monica A. Konerman, Shruti H. Mehta, Catherine G. Sutcliffe, Trang Vu, Yvonne Higgins, Michael S. Torbenson, Richard D. Moore, David L. Thomas, Mark S. Sulkowski – 20 September 2013 – Human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfection is associated with progressive liver disease. However, the rate of progression is variable and the ability to differentiate patients with stable versus progressive HCV disease is limited. The objective of this study was to assess the incidence of and risk factors for fibrosis progression in a prospective cohort of coinfected patients.

Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients

Luca Quagliata, Matthias S. Matter, Salvatore Piscuoglio, Leila Arabi, Christian Ruiz, Alfredo Procino, Michal Kovac, Francesca Moretti, Zuzanna Makowska, Tujana Boldanova, Jesper B. Andersen, Monika Hämmerle, Luigi Tornillo, Markus H. Heim, Sven Diederichs, Clemente Cillo, Luigi M. Terracciano – 20 September 2013 – Hepatocellular carcinoma (HCC) is among the leading causes of cancer‐related death. Despite the advances in diagnosis and management of HCC, the biology of this tumor remains poorly understood.

Incidence and long‐term risk of de novo malignancies after liver transplantation with implications for prevention and detection

Harald Schrem, Marlene Kurok, Alexander Kaltenborn, Arndt Vogel, Ulla Walter, Lea Zachau, Michael P. Manns, Jürgen Klempnauer, Moritz Kleine – 14 September 2013 – The goal of this study was the characterization of long‐term cancer risks after liver transplantation (LT) with implications for prevention and detection.

Outcomes for recipients of liver transplantation for alpha‐1‐antitrypsin deficiency–related cirrhosis

Elizabeth J. Carey, Vivek N. Iyer, Darlene R. Nelson, Justin H. Nguyen, Michael J. Krowka – 10 September 2013 – Alpha‐1‐antitrypsin (AAT) deficiency is a rare genetic disease caused by an abnormal production of the serine protease inhibitor AAT. Liver transplantation (LT) cures cirrhosis caused by AAT deficiency and restores the normal production of AAT. There are few reports on the post‐LT outcomes of patients with AAT deficiency. The aim of this study was to determine the characteristics and outcomes of patients undergoing LT for AAT deficiency at 3 large transplant centers.

Subscribe to